A Randomized, Open-Label Phase III Study of Azenosertib versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Shelly Seward, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07546500

Objective

Evaluate progression-free survival in subjects randomized to azenosertib versus Investigator s choice of chemotherapy

Share:

Related Clinical Trials

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination with Rilvegostomig in Participants with High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04)
An Interventional Phase III, Open-Label, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Advanced or Recurrent Mismatch Repair Proficient Endometrial Cancer
Study of a New Device for Severe Asthma (PULSAR)
Multicenter research for the application and verification of the performance of the Necker Cranial Injury Scale (NCIS) as a predictor of in-hospital mortality in children and adolescents (<17 y-o) with severe traumatic brain injury (sTBI)